Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 264

Results For "Pan"

9224 News Found

Biohaven disappointed as rare disease therapy faces FDA setback 'despite promising results'
Drug Approval | November 10, 2025

Biohaven disappointed as rare disease therapy faces FDA setback 'despite promising results'

The FDA setback highlights ongoing tensions between patient needs, regulatory processes, and the use of real-world evidence in evaluating treatments for rare diseases


Novo Nordisk India partners with Emcure to commercialise Poviztra in India
News | November 10, 2025

Novo Nordisk India partners with Emcure to commercialise Poviztra in India

Poviztra is a second brand of Wegovy


Glenmark secures China approval for Ryaltris
Drug Approval | November 10, 2025

Glenmark secures China approval for Ryaltris

The approval granted with zero supplementation requests is an important milestone in Glenmark’s respiratory pipeline


Marksans Pharma's Goa unit clears FDA inspection
News | November 10, 2025

Marksans Pharma's Goa unit clears FDA inspection

The said inspection concluded with Zero Form 483 observation


Poly Medicure posts Q2 FY26 consolidated net profit at Rs. 91.83 Cr
News | November 09, 2025

Poly Medicure posts Q2 FY26 consolidated net profit at Rs. 91.83 Cr

Poly Medicure has reported total income of Rs. 477.82 crore during the period ended September 30, 2025


Syngene International reports Q2 FY26 consolidated PAT at Rs. 67.1 Cr
News | November 09, 2025

Syngene International reports Q2 FY26 consolidated PAT at Rs. 67.1 Cr

Syngene International has reported total income of Rs. 926 crore during the period ended September 30, 2025


Piramal Pharma posts Q2 FY26 consolidated loss at Rs. 99.22 Cr
News | November 09, 2025

Piramal Pharma posts Q2 FY26 consolidated loss at Rs. 99.22 Cr

Piramal Pharma has reported total income of Rs. 2,109.32 crore during the period ended September 30, 2025


Solara Active Pharma Sciences posts Q2 FY26 consolidated loss at Rs. 10.10 Cr
News | November 09, 2025

Solara Active Pharma Sciences posts Q2 FY26 consolidated loss at Rs. 10.10 Cr

Solara Active Pharma Sciences has reported total income of Rs. 314.03 crore during the period ended September 30, 2025


Caplin Point Laboratories reports Q2 FY26 consolidated PAT at Rs. 154.45 Cr
News | November 09, 2025

Caplin Point Laboratories reports Q2 FY26 consolidated PAT at Rs. 154.45 Cr

Caplin Point Laboratories has reported total income of Rs. 564.41 crore during the period ended September 30, 2025


SMS Pharmaceuticals post Q2 FY26 consolidated PAT at Rs. 25.31 Cr
News | November 09, 2025

SMS Pharmaceuticals post Q2 FY26 consolidated PAT at Rs. 25.31 Cr

SMS Pharmaceuticals has reported total income of Rs. 243.86 crore during the period ended September 30, 2025